Novartis | Kostnadene For Salg

Cost Of Sales Endring Dato
AbbVie USD 4.09B 181M 2024-03
Alcon AG USD 1.08B 9M 2024-03
Almirall EUR 90.2M 15.9M 2024-03
Amgen USD 3.2B 88M 2024-03
AstraZeneca USD 2.22B 63M 2024-03
Bayer EUR 5.46B 977M 2024-03
Biogen USD 542.2M 76.1M 2024-03
Bristol-Myers Squibb USD 2.93B 225M 2024-03
Eli Lilly USD 1.67B 114.5M 2024-03
Fresenius EUR 4.3B 83M 2024-03
Fresenius Medical Care EUR 3.55B 87.13M 2024-03
Galapagos EUR 2.55M 3.15M 2024-03
Genmab DKK 185M 59M 2024-03
Gilead Sciences USD 1.55B 59M 2024-03
GlaxoSmithKline GBP 1.97B 363M 2024-03
GRIFOLS EUR 1.08B 114.07M 2023-12
Hikma Pharmaceutical USD 694M 32M 2023-06
J&J USD 6.51B 287M 2024-03
Lonza CHF 1.97B 29M 2023-06
Merck EUR 2.11B 216M 2024-03
Merck USD 3.54B 200M 2024-03
Novartis USD 3.1B 109M 2024-03
Novartis USD 3.1B 109M 2024-03
Orion EUR 137.9M 8.1M 2024-03
Pfizer USD 3.38B 3.29B 2024-03
Philips EUR 2.32B 940M 2024-03
Recordati EUR 192.26M 13.72M 2024-03
Regeneron Pharmaceuticals USD 433.8M 83.2M 2024-03
Roche Holding CHF 7.62B 1.33B 2023-06
Sanofi EUR 3.44B 402M 2024-03
UCB EUR 802M 27M 2023-06



Novartis Kostnadene For Salg - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Jun 2024.